Alkem Laboratories Ltd. sees a credit rating action
TL;DR
What percentage of Alkem’s total US revenue is derived from products manufactured specifically at the Amaliya, Daman facility, and how does this compare to the revenue contribution of the company's other US-FDA approved sites?
Alkem Laboratories does not publicly disclose the specific percentage of total US revenue derived from its Amaliya, Daman manufacturing facility, nor does it provide a facility-wise revenue contribution breakdown for its other US-FDA approved sites.
Regulatory Status and Known Context
- Amaliya, Daman Facility: The US FDA classified the site as Official Action Indicated (OAI) following an inspection conducted from April 20, 2026, to May 1, 2026, which yielded seven observations [1].
- Operational Status: Management reported that the facility continues to manufacture and supply approved products to the US market while the company works with the regulator to address the observations and achieve fully compliant status [1].
Disclosure Gap
Because official filings do not break down revenue contributions by individual manufacturing site or facility, the exact financial exposure and concentration risk tied to the Amaliya, Daman plant remain unquantified in public disclosures.
How does the current OAI classification at the Amaliya facility compare to the historical remediation timelines and financial impact (in terms of R&D/compliance spend) observed during previous US FDA regulatory actions at Alkem’s other manufacturing sites?
The US FDA classified Alkem Laboratories' manufacturing facility in Amaliya, Daman, as Official Action Indicated (OAI) following an inspection conducted from April 20, 2026, to May 1, 2026, which yielded seven observations [1].
Current Status and Operational Impact
- Regulatory Status: Classified as OAI by the US FDA, as communicated on August 6, 2026 [1].
- Commercial Continuity: The facility continues to manufacture and supply approved products to the U.S. market while the company works with the regulator to address observations [1].
Historical Remediation Timelines and Financial Impact
Data regarding historical remediation timelines, past regulatory actions at Alkem's other manufacturing sites, and specific financial expenditures on R&D or compliance related to previous FDA remediation are not reported in the current corporate disclosures.
Analytical Implications
While the OAI classification represents a formal escalation in regulatory scrutiny that typically pauses new product approvals from the affected site, the ongoing supply of existing approved products limits immediate revenue disruption [1]. Without historical disclosures on prior plant remediation costs or resolution timelines at other Alkem facilities, the duration of the OAI status and its eventual financial toll on compliance overhead remain uncertain.
Sources
- [1]Alkem Laboratories: US FDA classifies Amaliya, Daman manufacturing facility as Official Action Indicated (OAI) — 2026-08-06T11:02:44.460000, p.1
- [2]TTM Revenue INR
- [3]TTM EBITDA
Keep digging
